Signalisation PI3K/Akt/mTOR
Les inhibiteurs de la signalisation PI3K/Akt/mTOR sont des composés qui ciblent les voies de la phosphoinositide 3-kinase (PI3K), de la kinase Akt et de la cible de la rapamycine chez les mammifères (mTOR). Ces voies sont des régulateurs critiques de la croissance cellulaire, de la survie, du métabolisme et de l'autophagie, ce qui en fait des cibles clés dans la recherche sur le cancer et les troubles métaboliques. Inhiber ces voies peut aider à contrôler la croissance et la prolifération tumorales, offrant ainsi des stratégies thérapeutiques potentielles pour divers cancers et autres maladies caractérisées par une signalisation cellulaire dysrégulée. Chez CymitQuimica, nous offrons une sélection complète d'inhibiteurs de haute qualité de PI3K/Akt/mTOR pour soutenir vos recherches en oncologie, signalisation cellulaire et maladies métaboliques.
Sous-catégories appartenant à la catégorie "Signalisation PI3K/Akt/mTOR"
- AMPK(158 produits)
- ATM/ATR(71 produits)
- ADN-PK(51 produits)
- EGFR(572 produits)
- MELK(7 produits)
- PDK(9 produits)
- PI3K(242 produits)
- S6 Kinase(9 produits)
- gsk-3(112 produits)
- mTOR(144 produits)
Affichez 2 plus de sous-catégories
1038 produits trouvés pour "Signalisation PI3K/Akt/mTOR"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
Andamertinib
CAS :<p>Andamertinib is an EGFR inhibitor with antitumor activity.</p>Formule :C31H36N8O3Couleur et forme :SolidMasse moléculaire :568.669EGFR-IN-135
<p>EGFR-IN-135 (compound 3d) is an EGFR inhibitor with an IC50 value of 0.086 µM. It inhibits cell growth and arrests the cell cycle in the S phase in breast cancer cell lines.</p>Formule :C12H14N4OS2Couleur et forme :SolidMasse moléculaire :294.4Tyrphostin 63
CAS :<p>Tyrphostin 63 (compound 13) is an epidermal growth factor receptor (EGFR) inhibitor, with an IC50 of 375 μM and a Ki of 123 μM.</p>Formule :C10H8N2OCouleur et forme :SolidMasse moléculaire :172.183EGFR-IN-125
CAS :<p>EGFR-IN-125 (example 37) is a potent EGFR inhibitor with IC50 values of <0.3 nM for EGFR(d746-750/T790M/C797S), 0.52 nM for EGFR(L858R/T790M/C797S), 0.5 nM for EGFR(d746-750/C797S), 0.69 nM for EGFR(L858R/C797S), and 0.92 nM for EGFR (wild type).</p>Formule :C30H26N8OCouleur et forme :SolidMasse moléculaire :514.58PI3K-IN-27
CAS :<p>PI3K-IN-27 is a potent PI3K inhibitor, relevant for cancer and immune disease research. See patent WO2021233227A1.</p>Formule :C30H26F2N6O2SCouleur et forme :SolidMasse moléculaire :572.63PI3Kβ-IN-1
CAS :<p>PI3Kβ-IN-1 is a selective, orally active PI3Kβ inhibitor (IC50: 2 nM).</p>Formule :C25H14F2N8Couleur et forme :SolidMasse moléculaire :464.43ETP-47037
CAS :<p>ETP-47037: strong PI3Kα inhibitor (IC50: 0.99 nM), also targets PI3Kβ, δ, γ; may protect telomeres.</p>Formule :C20H27N9O3SCouleur et forme :SolidMasse moléculaire :473.55GSK3-IN-9
CAS :<p>GSK3-IN-9 (0713) is a selective inhibitor of glycogen synthase kinase 3 (GSK3). It holds potential for research into fragile X syndrome, attention deficit hyperactivity disorder (ADHD), childhood epilepsy, intellectual disabilities, diabetes, acute myeloid leukemia (AML), autism, and mental disorders.</p>Formule :C18H20N4OCouleur et forme :SolidMasse moléculaire :308.378EGFR-IN-48
<p>EGFR-IN-48: potent EGFR inhibitor, oral, IC50: 0.193-66.7 nM, blocks EGFR mutants & BaF3/PC-9 cell proliferation.</p>Couleur et forme :SolidEGFR-IN-34
<p>EGFR-IN-34 is a low-toxicity, acrylamide derivative antitumor agent that is a potent inhibitor of EGFR.</p>Formule :C26H27ClN6O2Couleur et forme :SolidMasse moléculaire :490.98PI3K-IN-26
CAS :<p>PI3K-IN-26 is an effective PI3K inhibitor. PI3K-IN-26 inhibits the proliferation of SU-DHL-6 cells, IC50= 36 nM.</p>Formule :C21H18N6OSCouleur et forme :SolidMasse moléculaire :402.47EGFR-IN-133
CAS :<p>EGFR-IN-133 (Compound 24) serves as an inhibitor targeting various mutations of the EGFR, including the wild type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with respective IC50 values of 0.1, 0.044, 0.036, 0.04, and 0.054 nM. The compound exhibits favorable pharmacokinetic properties and high oral bioavailability.</p>Formule :C27H29F2N7O3Couleur et forme :SolidMasse moléculaire :537.56EGFR-IN-132
CAS :<p>EGFR-IN-132 (Compound 23) is an EGFR inhibitor effective against various EGFR mutations including the wild-type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with IC50 values of 1.6, 0.025, 0.019, 0.022, and 0.029 nM, respectively. This compound demonstrates favorable pharmacokinetics with high oral bioavailability.</p>Formule :C27H31N7O3Couleur et forme :SolidMasse moléculaire :501.58EGFR-IN-139
CAS :<p>EGFR-IN-139 (compound PD 18) is an EGFR inhibitor with IC50 values of 12.88 nM (wild type), 10.84 nM (L858R/T790M), and 42.68 nM (L858R/T790M/C797S). It demonstrates significant anticancer activity against the A549 and H1975 cancer cell lines, which express high levels of EGFR. EGFR-IN-139 exhibits strong selectivity for cancer cells and can be utilized in research on non-small cell lung cancer (NSCLC).</p>Formule :C27H25ClN2O4Couleur et forme :SolidMasse moléculaire :476.951Tarloxotinib bromide
CAS :<p>Tarloxotinib bromide (TH-4000) is an irreversible inhibitor of EGFR/HER2.</p>Formule :C24H24Br2ClN9O3Degré de pureté :99.52%Couleur et forme :SolidMasse moléculaire :681.77Vps34-IN-3
<p>Vps34-IN-3 is a potent, selective, and orally bioavailable inhibitor of VPS34 kinase .</p>Formule :C14H20N4O2Couleur et forme :SolidMasse moléculaire :276.33EGFR-IN-18
<p>EGFR-IN-18 strongly inhibits L858R/T790M/C797S mutant EGFR (4.9 nM) and also targets wild-type EGFR (47 nM).</p>Formule :C33H28N6O3SCouleur et forme :SolidMasse moléculaire :588.68PI3kδ inhibitor 1
CAS :<p>PI3kδ inhibitor 1 is a selective inhibitor of PI3Kδ (IC50 of 3.8 nM).</p>Formule :C28H33FN6O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :504.60PI4KIIIbeta-IN-11
CAS :<p>PI4KIIIbeta-IN-11 is a PI4KIIIβ inhibitor (mean pIC50=9.1) that can be used to study diseases caused by RNA viruses and Plasmodium falciparum.</p>Formule :C33H39N7O3Couleur et forme :SolidMasse moléculaire :581.71SST0116CL1
CAS :<p>SST0116CL1 is an HSP90 inhibitor (IC50: 0.21 μM) that targets the ATP-binding pocket of Hsp90, disrupting its chaperone function and leading to the degradation of client proteins (EGFR, CDK4, and AKT). It induces the degradation of Her2 in BT-474 cells (IC50: 0.2 μM) and exhibits antiproliferative activity, inhibiting tumor growth.</p>Formule :C22H31ClN4O6Couleur et forme :SolidMasse moléculaire :482.96EGFR-IN-149
CAS :<p>EGFR-IN-149 (Compound 3-OH) is an EGFR inhibitor with an IC50 value of 0.42 nM.</p>Formule :C16H15N3OSCouleur et forme :SolidMasse moléculaire :297.375NS-062
CAS :<p>NS-062 is an orally effective, irreversible covalent inhibitor targeting EGFR, demonstrating antiproliferative activity in the resistant double mutant H1975 cells with an IC50 of 0.19 μM. It also exhibits antitumor activity in a murine H1975 xenograft model.</p>Formule :C28H30Cl2F2N6O4Couleur et forme :SolidMasse moléculaire :623.48PF-5177624
CAS :<p>PF-5177624 is a selective and potent PDK1 inhibitor inducing anti-tumor activity in breast cancer cells.</p>Formule :C25H25FN8O2Couleur et forme :SolidMasse moléculaire :488.52GSK-3β inhibitor 25
CAS :<p>GSK-3β inhibitor25 (Compound 6h) exhibits weak inhibitory activity against GSK-3β with an IC50 greater than 100 μM.</p>Formule :C16H15NOSCouleur et forme :SolidMasse moléculaire :269.361EGFR-IN-159
CAS :<p>EGFR-IN-159 (compound 12) is a dihydropyrimidine and a potent EGFR inhibitor with an IC50 of 29.00 nM. It exhibits dose-dependent inhibition of EGFR and HER2. The compound shows cytotoxicity against MCF-7 breast cancer cells and Vero cells with IC50 values of 16.07 μg/mL and 35.98 μg/mL, respectively. EGFR-IN-159 does not cross the blood-brain barrier (BBB) and demonstrates significant anticancer activity.</p>Formule :C21H23N3O5Couleur et forme :SolidMasse moléculaire :397.4244-FPBUA
CAS :<p>4-FPBUA, a semi-synthetic analog of lichen acid, enhances the functionality of cell-based blood-brain barriers (BBB) and increases the transport of β-amyloid (Aβ) in monolayer cells. Additionally, it acts as an inhibitor of mTOR, enhancing cellular autophagy (Autophagy) which can reverse BBB disruption in vivo, making it relevant for research in Alzheimer's disease.</p>Formule :C31H23FO7Couleur et forme :SolidMasse moléculaire :526.51DNA-PK-IN-2
CAS :<p>DNA-PK-IN-2 is an inhibitor of the DNA-PK enzyme complex, useful in cancer research.</p>Formule :C20H23N5O3Couleur et forme :SolidMasse moléculaire :381.43HER2-IN-8
CAS :<p>HER2-IN-8 is an inhibitor of HER-2 that can be used in the study of cancer and inflammation-related diseases.</p>Formule :C26H25F2N9O3Couleur et forme :SolidMasse moléculaire :549.53NSC381467
CAS :<p>NSC381467: Potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.</p>Formule :C20H16O7Couleur et forme :SolidMasse moléculaire :368.34PD-M6
CAS :<p>PD-M6 is an mTOR PROTAC degrader with a DC50 of 4.8 μM, which facilitates the ubiquitination and degradation of mTOR. It inhibits the proliferation of cancer cell lines HeLa, MCF-7, and HepG2 with IC50 values of 11.3, 2.58, and 3.23 μM, respectively, and induces autophagy. Additionally, PD-M6 specifically targets the degradation of the key protein LAMTOR1 in the mTOR signaling pathway.</p>Formule :C30H39N9O6Couleur et forme :SolidMasse moléculaire :621.69BPI-15086
CAS :<p>BPI-15086 is an orally active, effective, irreversible inhibitor selective for mutations, targeting both EGFR and the T790M resistance mutation tyrosine kinase. It can be utilized in the study of non-small cell lung cancer.</p>Formule :C29H33ClN8O4Couleur et forme :SolidMasse moléculaire :593.08BML-265
CAS :<p>BML-265 is a potent inhibitor of EGFR tyrosine kinase (EGFR tyrosine kinase). It disrupts Golgi apparatus integrity in human cells and hinders the transport of secretory proteins across various substances. In contrast, BML-265 does not affect the integrity and transport of the Golgi apparatus in rodent cells.</p>Formule :C18H15N3O2Couleur et forme :SolidMasse moléculaire :305.331GSK3β-IN-2
CAS :<p>GSK3β-IN-2 (Compound S01) is an inhibitor of GSK3β with an IC50 of 0.35 nM. It activates the Wnt/β-catenin signaling pathway, promoting neurogenesis and neurite outgrowth. GSK3β-IN-2 reduces tau protein phosphorylation induced by Aβ at the Ser396 site, thereby decreasing neurofibrillary tangles. Furthermore, GSK3β-IN-2 improves Alzheimer's disease symptoms in a zebrafish model.</p>Formule :C25H18N4OCouleur et forme :SolidMasse moléculaire :390.437PI3K-IN-37
CAS :<p>PI3K-IN-37 inhibits PI3K α/β/δ (IC50: 6/8/4 nM) and mTOR (IC50: 4 nM).</p>Formule :C25H26N6O2Couleur et forme :SolidMasse moléculaire :442.51DNA-PK-IN-9
<p>DNA-PK-IN-9 (YK6) is a potent DNA-PK inhibitor with an IC50 of 10.47 nM, important in cancer research.</p>Formule :C21H21N5O2Couleur et forme :SolidMasse moléculaire :375.42EGFR/HER2-IN-5
<p>EGFR/HER2-IN-5: Irreversible, oral dual EGFR inhibitor, IC50 0.6 nM, targets L858R/T790M mutations, anti-tumor in vivo for lung cancer study.</p>Couleur et forme :SolidEGFR-IN-24
<p>EGFR-IN-24 is a potent inhibitor of EGFR and inhibits EGFR (del19/T790M/C797S) and EGFR (L858R/T790M/C797S).</p>Formule :C30H35FN6O3Couleur et forme :SolidMasse moléculaire :546.64NU5455
CAS :<p>NU5455 is a potent DNA-PKcs inhibitor, oral, boosts doxorubicin in liver tumors, amplifies topoisomerase inhibitors, no adverse effects.</p>Formule :C34H33N3O5SCouleur et forme :SolidMasse moléculaire :595.71EGFR/HER2-IN-8
<p>EGFR/HER2-IN-8 inhibits EGFR, HER2, DHFR (IC50: 0.45, 0.244, 5.669 μM); useful in cancer research, safe and selective.</p>Formule :C16H16N4O2SCouleur et forme :SolidMasse moléculaire :328.39D-69491 hydrochloride
CAS :<p>D-69491 hydrochloride is an inhibitor of HER-2 tyrosine kinase activity, blocking the phosphorylation of HER-2 and inhibiting the proliferation of SKOV-3 cells. It exhibits antitumor activity.</p>Formule :C25H26Cl2FN7O3Couleur et forme :SolidMasse moléculaire :562.42GSK3β-IN-1
CAS :<p>GSK3β-IN-1 (compound 1) is an inhibitor of glycogen synthase kinase-3β (GSK-3β) with an IC50 value of 65 nM, and it is utilized in Alzheimer's disease research.</p>Formule :C17H13FN2O4SCouleur et forme :SolidMasse moléculaire :360.36GSK-3β inhibitor 7
<p>GSK-3β inhibitor 7 is a GSK-3β inhibitor (IC50: 5.25 μM).</p>Formule :C27H23BrN4O2SCouleur et forme :SolidMasse moléculaire :547.47EGFR-IN-35
CAS :<p>EGFR-IN-35, an acrylamide-based EGFR inhibitor, shows promise for EGFR mutation-related cancers like NSCLC.</p>Formule :C25H24ClN7O2Couleur et forme :SolidMasse moléculaire :489.96GSK-3β inhibitor 26
CAS :<p>GSK-3β inhibitor26 (Compound D14) is a GSK-3β inhibitor with an IC50 of 18.23 μM. This compound is applicable in research related to cancer, inflammation, and neurodegenerative diseases.</p>Formule :C15H11N3O3Couleur et forme :SolidMasse moléculaire :281.266Pred17
<p>Pred17 is an effective EGFR inhibitor with potential applications in lung cancer research.</p>Formule :C27H22BN3OCouleur et forme :SolidMasse moléculaire :415.29EGFR-IN-126
CAS :<p>EGFR-IN-126 (compound 9d) is an effective inhibitor of EGFR L858R/T790M/C797S, displaying an IC50 value of 0.005 μM. It exhibits antitumor activity both in vivo and in vitro.</p>Formule :C28H28BrFN4O3Couleur et forme :SolidMasse moléculaire :567.45SIK2-IN-3
CAS :<p>SIK2-IN-3 is an orally active selective inhibitor of SIK1/2 with IC50 values of 0.128/0.084 μM. It hinders the phosphorylation of CRTC3 and suppresses the production of pro-inflammatory factors in myeloid cells. Additionally, SIK2-IN-3 alleviates systemic and tissue inflammatory responses in a mouse anti-CD40 colitis model.</p>Formule :C23H24N6O2Couleur et forme :SolidMasse moléculaire :416.48HER2-IN-21
CAS :<p>HER2-IN-21 (compound 657994) is an inhibitor of the human epidermal growth factor receptor 2 (HER2) with an IC50 value of 3.85 μM.</p>Formule :C20H18N4O3SCouleur et forme :SolidMasse moléculaire :394.447GSK-3β inhibitor 6
<p>GSK-3β inhibitor 6 is a highly potent inhibitor of GSK-3β, with an IC50 value of 24.4 μM.</p>Formule :C20H17BrN4Couleur et forme :SolidMasse moléculaire :393.28GSK-3β inhibitor 20
CAS :<p>GSK-3β inhibitor20 (compound 3A) is an effective inhibitor of GSK-3β, exhibiting an IC50 value of 74.4 nM.</p>Formule :C22H21N5O2SCouleur et forme :SolidMasse moléculaire :419.50
